[{"id":"9a08485b-b8fa-4035-b77f-9d260c28ce59","acronym":"","url":"https://clinicaltrials.gov/study/NCT00896480","created_at":"2021-01-18T03:26:13.770Z","updated_at":"2024-07-02T16:36:32.176Z","phase":"Phase 2","brief_title":"Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma","source_id_and_acronym":"NCT00896480","lead_sponsor":"GlaxoSmithKline","biomarkers":" ALK • CD8 • IFNG • TNFA • CD4 • MAGEA3","pipe":"","alterations":" ","tags":["ALK • CD8 • IFNG • TNFA • CD4 • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2009","start_date":" 05/19/2009","primary_txt":" Primary completion: 11/03/2014","primary_completion_date":" 11/03/2014","study_txt":" Completion: 11/03/2014","study_completion_date":" 11/03/2014","last_update_posted":"2021-04-08"},{"id":"93524cf9-a66e-4507-b9c9-063ac316366a","acronym":"PREDICT","url":"https://clinicaltrials.gov/study/NCT00942162","created_at":"2021-01-18T03:39:27.818Z","updated_at":"2024-07-02T16:36:37.713Z","phase":"Phase 2","brief_title":"A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma","source_id_and_acronym":"NCT00942162 - PREDICT","lead_sponsor":"GlaxoSmithKline","biomarkers":" ALK • MAGEA3","pipe":"","alterations":" ","tags":["ALK • MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 08/14/2009","start_date":" 08/14/2009","primary_txt":" Primary completion: 06/27/2012","primary_completion_date":" 06/27/2012","study_txt":" Completion: 04/01/2015","study_completion_date":" 04/01/2015","last_update_posted":"2020-12-08"},{"id":"e3c3481a-4a24-4334-a6f6-ce5a4ce224dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01266603","created_at":"2021-01-18T05:07:17.231Z","updated_at":"2025-02-25T13:16:31.595Z","phase":"Phase 2","brief_title":"High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI","source_id_and_acronym":"NCT01266603","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MAGEA3","pipe":"","alterations":" ","tags":["MAGEA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • Promune (agatolimod) • Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 02/22/2011","start_date":" 02/22/2011","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-19"},{"id":"6f649007-b4d2-4b1d-968c-db29ab2d4c39","acronym":"","url":"https://clinicaltrials.gov/study/NCT00290355","created_at":"2021-01-18T00:59:20.464Z","updated_at":"2024-07-02T16:36:51.968Z","phase":"Phase 2b","brief_title":"Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery","source_id_and_acronym":"NCT00290355","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumagev (astuprotimut-R)"],"overall_status":"Completed","enrollment":" Enrollment 182","initiation":"Initiation: 05/28/2002","start_date":" 05/28/2002","primary_txt":" Primary completion: 07/19/2011","primary_completion_date":" 07/19/2011","study_txt":" Completion: 07/19/2011","study_completion_date":" 07/19/2011","last_update_posted":"2020-01-02"}]